Effect of the JAK1 Inhibitor, Upadacitinib, on Skin Barrier Repair of Eczema Elicited During Anti-Interleukin-17 Treatment for Psoriasis
Dermatitis® · 2024
DOI: 10.1089/derm.2023.0298 ↗Kurz gefasst
Fallbericht in der Zeitschrift Dermatitis®, 2024. Verfasst von Shuhong Ye und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, China. Hauptthemen laut MEDLINE: Psoriasis, Heterocyclic Compounds, 3-Ring, Interleukin-17, Eczema. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, China.
- Department of Dermatology, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
- Department of Neurology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, China.
- Department of Dermatology, Xi'an International Medical Center Hospital, Xi'an, China.
ORCID-Profile: Shuhong Ye
Zitieren
APA
Ye, S., Yu, B., Wu, J., Xu, Z., Xu, B., Sun, H., & Zhao, B. (2024). Effect of the JAK1 Inhibitor, Upadacitinib, on Skin Barrier Repair of Eczema Elicited During Anti-Interleukin-17 Treatment for Psoriasis. Dermatitis®. https://doi.org/10.1089/derm.2023.0298
Vancouver
Ye S, Yu B, Wu J, Xu Z, Xu B, Sun H, et al. Effect of the JAK1 Inhibitor, Upadacitinib, on Skin Barrier Repair of Eczema Elicited During Anti-Interleukin-17 Treatment for Psoriasis. Dermatitis®. 2024. doi:10.1089/derm.2023.0298
BibTeX
@article{Ye2024,
author = {Ye, Shuhong and Yu, Biao and Wu, Jiawen and Xu, Zining and Xu, Bingyang and Sun, Hong and Zhao, Bin},
title = {Effect of the JAK1 Inhibitor, Upadacitinib, on Skin Barrier Repair of Eczema Elicited During Anti-Interleukin-17 Treatment for Psoriasis},
journal = {Dermatitis®},
year = {2024},
doi = {10.1089/derm.2023.0298}
}
EUVIMED